{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:34:15Z","timestamp":1791995655722,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00011-025-02017-4","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T13:58:36Z","timestamp":1741442316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Interlukin-23 inhibitors as an induction and maintenance therapy for moderate to severe ulcerative colitis: a systematic review and meta\u2011analysis of randomized controlled trials"],"prefix":"10.1007","volume":"74","author":[{"given":"Omar","family":"Saab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Al-Obaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwah","family":"Algodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Algodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhareth","family":"Al-Sagban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder","family":"Alamily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nooraldin","family":"Merza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layth","family":"Alzubaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"DuPont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"2017_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2023.15389","volume":"330","author":"B Gros","year":"2023","unstructured":"Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023;330:951\u201365.","journal-title":"JAMA"},{"key":"2017_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.dld.2021.03.002","volume":"53","author":"A Armuzzi","year":"2021","unstructured":"Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review. Dig Liver Dis. 2021;53:803\u20138.","journal-title":"Dig Liver Dis"},{"key":"2017_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000496739","volume":"37","author":"S Danese","year":"2019","unstructured":"Danese S, Allez M, Van Bodegraven AA, Dotan I, Gisbert JP, Hart A, et al. Unmet medical needs in ulcerative colitis: an expert group consensus. Dig Dis. 2019;37:266\u201383.","journal-title":"Dig Dis"},{"key":"2017_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/ecco-jcc\/jjx117","volume":"12","author":"P Hindryckx","year":"2018","unstructured":"Hindryckx P, Vande Casteele N, Novak G, Khanna R, D\u2019Haens G, Sandborn WJ, et al. The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients? J Crohn\u2019s Colitis. 2018;12:105\u20139.","journal-title":"J Crohn\u2019s Colitis."},{"key":"2017_CR5","first-page":"1","volume":"14","author":"B Siegmund","year":"2021","unstructured":"Siegmund B, Peyrin-Biroulet L, Sandborn W, Panaccione R, Dom\u00e8nech E, Pouillon L, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021;14:1\u201322.","journal-title":"Therap Adv Gastroenterol"},{"key":"2017_CR6","doi-asserted-by":"crossref","unstructured":"Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to Anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7.","DOI":"10.1038\/ctg.2015.63"},{"key":"2017_CR7","unstructured":"Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. [cited 2024 Sep 10];2011:483\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21328309\/"},{"key":"2017_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"2017_CR9","doi-asserted-by":"publisher","first-page":"13056","DOI":"10.1002\/jgh3.13056","volume":"8","author":"O Saleh","year":"2024","unstructured":"Saleh O, Abuelazm MT, Mohamed I, Ramadan A, Assaf M, Alzoubi A, et al. Etrolizumab as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. JGH Open. 2024;8:13056.","journal-title":"JGH Open."},{"key":"2017_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00011-023-01829-6","volume":"73","author":"HA Suilik","year":"2023","unstructured":"Suilik HA, Jaber F, Abuelazm M, Ramadan A, Elzeftawy MA, Elrosasy A, et al. Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Inflamm Res. 2023;73:183\u201398.","journal-title":"Inflamm Res"},{"key":"2017_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40259-020-00451-w","volume":"34","author":"A Almradi","year":"2020","unstructured":"Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, et al. Clinical Trials of IL-12\/IL-23 inhibitors in inflammatory bowel disease. BioDrugs. 2020;34:713\u201321.","journal-title":"BioDrugs"},{"key":"2017_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/07853890.2011.577093","volume":"43","author":"E Duvallet","year":"2011","unstructured":"Duvallet E, Semerano L, Assier E, Falgarone G, Boissier MC. Interleukin-23: A key cytokine in inflammatory diseases. Ann Med. 2011;43:503\u201311.","journal-title":"Ann Med"},{"key":"2017_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","volume":"16","author":"AR Moschen","year":"2019","unstructured":"Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185\u201396.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2017_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14712598.2020.1697227","volume":"20","author":"J Han\u017eel","year":"2020","unstructured":"Han\u017eel J, D\u2019Haens GR. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2020;20:399\u2013406.","journal-title":"Expert Opin Biol Ther"},{"key":"2017_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/flgastro-2022-102168","volume":"13","author":"S Honap","year":"2022","unstructured":"Honap S, Al-Hillawi L, Baillie S, Bancil A, Matini L, Lau R, et al. Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. Frontline Gastroenterol. 2022;13:517\u201323.","journal-title":"Frontline Gastroenterol"},{"key":"2017_CR16","doi-asserted-by":"publisher","first-page":"II54","DOI":"10.1093\/ecco-jcc\/jjac007","volume":"16","author":"R Atreya","year":"2022","unstructured":"Atreya R, Neurath MF. IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality. J Crohn\u2019s Colitis. 2022;16:II54-63.","journal-title":"J Crohn\u2019s Colitis."},{"key":"2017_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","volume":"165","author":"L Peyrin-Biroulet","year":"2023","unstructured":"Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KH, et al. Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology. 2023;165:1443\u201357.","journal-title":"Gastroenterology"},{"key":"2017_CR18","unstructured":"Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel J-F, et al. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA 2024. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39037800%0A. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=PMC11264075"},{"key":"2017_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158:537-549.e10. https:\/\/doi.org\/10.1053\/j.gastro.2019.08.043.","journal-title":"Gastroenterology"},{"key":"2017_CR20","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355.","journal-title":"N Engl J Med"},{"key":"2017_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89.","journal-title":"Syst Rev"},{"key":"2017_CR22","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ WV (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2023."},{"key":"2017_CR23","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 [cited 2021 Jul 22];366. https:\/\/www.bmj.com\/content\/366\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2017_CR24","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ. Rating Quality of Evidence and Strength of Recommendations: What is \u201cquality of evidence\u201d and why is it important to clinicians? Br Med J. 2008 [cited 2021 Dec 23];336:995. Available from: \/labs\/pmc\/articles\/PMC2364804\/","DOI":"10.1136\/bmj.39490.551019.BE"},{"key":"2017_CR25","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating Quality of Evidence and Strength of Recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J. 2008 [cited 2021 Dec 23];336:924. Available from: \/labs\/pmc\/articles\/PMC2335261\/","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2017_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74:785\u201394.","journal-title":"Biometrics"},{"key":"2017_CR27","first-page":"795","volume":"3","author":"SV Kane","year":"2007","unstructured":"Kane SV. Overcoming adherence issues in ulcerative colitis. Gastroenterol Hepatol. 2007;3:795\u20139.","journal-title":"Gastroenterol Hepatol"},{"key":"2017_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/ecco-jcc\/jjv210","volume":"10","author":"K Ikeya","year":"2016","unstructured":"Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, et al. The ulcerative colitis endoscopic index of severity more accurately reflects clinical outcomes and long-term prognosis than the mayo endoscopic score. J Crohn\u2019s Colitis. 2016;10:286\u201395.","journal-title":"J Crohn\u2019s Colitis"},{"key":"2017_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cgh.2010.12.028","volume":"9","author":"S Ardizzone","year":"2011","unstructured":"Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483-489.e3. https:\/\/doi.org\/10.1016\/j.cgh.2010.12.028.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2017_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.5217\/ir.2016.14.3.202","volume":"14","author":"RJ Colman","year":"2016","unstructured":"Colman RJ, Rubin DT. Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review. Intest Res. 2016;14:202\u201310.","journal-title":"Intest Res"},{"key":"2017_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5217\/ir.2016.14.3.264","volume":"14","author":"S Bopanna","year":"2016","unstructured":"Bopanna S, Roy M, Das P, Dattagupta S, Sreenivas V, Mouli VP, et al. Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer. Intest Res. 2016;14:264\u20139.","journal-title":"Intest Res"},{"key":"2017_CR32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/gutjnl-2015-309598","volume":"65","author":"RV Bryant","year":"2016","unstructured":"Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, Von Herbay A, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408\u201314.","journal-title":"Gut"},{"key":"2017_CR33","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1053\/j.gastro.2007.03.104","volume":"132","author":"CO Elson","year":"2007","unstructured":"Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359\u201370.","journal-title":"Gastroenterology"},{"key":"2017_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/ng1954","volume":"39","author":"J Hampe","year":"2007","unstructured":"Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207\u201311.","journal-title":"Nat Genet"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02017-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:53:47Z","timestamp":1767200027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-025-02017-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2017"],"URL":"https:\/\/doi.org\/10.1007\/s00011-025-02017-4","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"50"}}